# Angiotensin II

Canonical source: https://retacompare.com/encyclopedia/angiotensin-ii

Activates AT1 receptor (vasoconstriction, aldosterone release, sodium retention) and AT2 receptor (counter-regulatory).

Reference facts

Also known asGiaprezaCategoryNeuropeptide & OtherMechanism of actionActivates AT1 receptor (vasoconstriction, aldosterone release, sodium retention) and AT2 receptor (counter-regulatory).TargetsAT1R, AT2RIndications under research or approvedSeptic / vasodilatory shock (Giapreza)Regulatory status (reference entry)FDA-approved (Giapreza 2017)Half-life~15–30 seconds (native); 4 minutes for Giapreza infusion-correctedSequenceDRVYIHPFSequence notesOctapeptide; cleaved from Angiotensin I by ACE.Molecular weight (Da)1046Originator / sponsorLa Jolla Pharmaceutical (Innoviva)First reported1957
    Primary References

ATHOS-3, NEJM 2017


    Explore research articles about Angiotensin II


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- ATHOS-3, NEJM 2017: https://www.nejm.org/doi/full/10.1056/NEJMoa1704154